The International Con-Current Session of the First Tianjin International Cancer Conference successfully held in Tianjin in 2022
On September 2, 2022, the International Con-Current Session of the First Tianjin International Cancer Conference successfully held in Tianjin Medical University Cancer Institute & Hospital (TMUCIH). This session is hosted by China Anti-Cancer Association, and sponsored by Tianjin Medical University Cancer Institute & Hospital. Surrounding with the theme of the latest progress of clinical and translational research about gastrointestinal tumor and breast cancer in the world, the conference invited the speakers from German, United Kingdom, Singapore, Japan, and Russia to present insightful lectures via virtual platform.
The Vice President, Prof. Chen, Kexin chaired the opening ceremony. Prof. Hao, Jihui, the President of the TMUCIH, introduced the integrated development strategy and general information about hospital. Prof. Hao expressed his gratitude to welcome the international guests who came to join in the conference and he stated that the hospital will keep going to maintain the friendly collaboration with international partners in cancer treatment and science research, also explore the new partners even in the pandemic era.
The conference invited Prof. Lee, Soo Chin, the Associate Director of National University Cancer Institute (NCIS), Singapore, to share a experience about developing novel therapeutics and predictive biomarkers in breast cancer of NCIS; Prof. Michael Baumann, the Chairman of German Cancer Research Center (DKFZ), introduced the new developments in cancer research of DKFZ; Prof. Tony Ng, the Head of Comprehensive Cancer Center, King’ s College London, discussed the integrative imaging-OMIC combination approach to probe tumor cell/micro-environment changes for recurrent cancer detection and treatment; Prof. Kazuaki Shimada, the Director of National Cancer Center Hospital (NCCH), Japan, analyzed the recent trends in surgical treatment and chemotherapy for pancreatic cancer in NCCH; Prof. Petr Krivorotko, the Head of Breast Cancer Surgical Department of N.N. Petrov National Medical Research Center of Oncology, Russia, talked about the global status of breast cancer and Russian experience. Prof. Wang, Liwei, the Director of Pancreatic Cancer Diagnosis and Treatment Center of Shanghai Jiao Tong University delivered the Renji study on immunotherapy exploration in pancreatic cancer.
Besides that, the leading experts in TMUCIH, such as Prof. Liang, Han, the Director of Gastric Cancer Center presented the lecture about the conversion therapy for stage IV gastric cancer; Prof. Zhang, Jin, the Director of Department of Breast Cancer III, introduced the strategy and quality control system for early detection and treatment of breast cancer in Chinese women; Prof. Song, Tianqiang, the Director of Department of Hepatobiliary Cancer, shared the consensus of Chinese experts and Tianjin experience sharing on conversion therapy of liver cancer.
Over 70,000 delegates attended online and on-site. The conference promoted the academic exchanges between TMUCIH and international partners, and it would be a new milestone for establishing an international virtual platform to have a further conversation in oncology research and development.